ロード中...
Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
Melphalan flufenamide (hereinafter referred to as “melflufen”) is a peptide‐conjugated drug currently in phase 3 trials for the treatment of relapsed or refractory multiple myeloma. Due to its lipophilic nature, it readily enters cells, where it is converted to the known alkylator melphalan leading...
保存先:
| 出版年: | Cancer Med |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520280/ https://ncbi.nlm.nih.gov/pubmed/32717133 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3300 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|